Lv41
488 积分 2026-01-06 加入
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy
2小时前
待确认
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
4天前
已完结
CHRONIC TREATMENT WITH THE NOVEL SARCOMERE MODULATOR EDG-7500 IMPROVES LEFT VENTRICULAR DISTENSIBILITY AND CARDIAC OUTPUT RECRUITMENT UNDER STRESS IN A MINIPIG GENETIC MODEL OF NON-OBSTRUCTED HYPERTROPHIC CARDIOMYOPATHY
5天前
已关闭
EDG-7500, A First-in-Class Cardiac Sarcomere Modulator, Demonstrates Favorable Tolerability, Safety, And Pharmacokinetics In Healthy Adults
5天前
已完结
A Literature-Based Study of Tardive Dyskinesia- From Pathogenesis to Treatment
1个月前
已完结
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy
1个月前
已完结
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy
1个月前
已完结
Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611)
2个月前
已完结
Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-γ8-associated AMPA receptors
2个月前
已完结
JNJ-55511118 Stabilizes a Desensitized-like Conformation of γ8-Containing AMPA Receptors through Long-Range Allosteric Modulation
3个月前
已完结
皖公网安备34019202002308
